Strides Shasun on Wednesday said that it will launch Ranitidine tablets USP, 75 mg (OTC) for the US markets. Strides is already a key player with 32 per cent share of the US Rx market for Ranitidine.
According to IRI data, the US OTC market for Ranitidine tablets, which is the generic form of the popular brand Zantac, is approximately $200 million, the company said in a statement.
This is the second product approval from the company’s 50:50 joint venture with Vivimed Labs.